dyslipidemia
Conditions
Interventions
Pitavastatin 2 mg/day for 6 months
EPA 1800 mg/day for 6 months
Sponsors
University of Fukui Faculty of Medical Sciences, Division of cardiovascular Medicine
Kanazawa Medical University Hospital The 21st Century Multidisciplinary Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1,Dyslipidemic patients whose serum LDL-C levels are more than 140 mg/dL or TC levels are more than 220 mg/dL 2,Patients who provided written informed consent. The study protocol was approved by the Ethics Committee of Fukui University.
Exclusion criteria
Exclusion criteria: 1,pregnant, breast feeding, or could be pregnant 2,severe liver diseases 3,severe kidney diseases (eGFR<30 mL/min/1.73m2) 4,history of allergic reaction to Pitavastatin or EPA 5,Physician does not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison of changes of LOX-1 ligand density and MT1-MMP expression rate | — |
Secondary
| Measure | Time frame |
|---|---|
| comparison of change or %change of TC, TG, HDL-C, LDL-C, hs-CRP, sLOX-1 density and the fatty acid compartment | — |
Countries
Japan
Contacts
Public ContactHiroyasu Uzui
University of Fukui Faculty of Medical Sciences Division of cardiovascular Medicine
Outcome results
None listed